NASDAQ:SPHS - Sophiris Bio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.79 +0.06 (+1.61 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$3.73
Today's Range$3.71 - $3.82
52-Week Range$1.80 - $4.05
Volume391,100 shs
Average Volume306,472 shs
Market Capitalization$112.92 million
P/E Ratio-9.48
Dividend YieldN/A
Sophiris Bio logoSophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio1.30
Current Ratio5.90
Quick Ratio5.90


Trailing P/E Ratio-9.48
Forward P/E Ratio-7.43
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book15.16


EPS (Most Recent Fiscal Year)($0.40)
Net Income$-8,620,000.00
Net MarginsN/A
Return on Equity-138.96%
Return on Assets-48.63%


Outstanding Shares30,110,000

Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How were Sophiris Bio's earnings last quarter?

Sophiris Bio (NASDAQ:SPHS) issued its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.02. View Sophiris Bio's Earnings History.

What price target have analysts set for SPHS?

2 equities research analysts have issued 12-month target prices for Sophiris Bio's shares. Their predictions range from $6.00 to $8.00. On average, they anticipate Sophiris Bio's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Sophiris Bio.

Who are some of Sophiris Bio's key competitors?

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the folowing people:
  • Mr. Randall E. Woods, Pres, CEO & Director (Age 66)
  • Mr. Peter T. Slover CPA, Chief Financial Officer (Age 43)
  • Dr. Allison J. Hulme Ph.D., COO, Head of R&D and Director (Age 55)
  • Dr. Samuel R. Denmeade M.D., Chief Scientific Officer and Member of the Scientific Advisory Board
  • Dr. James Joseph Beesley BSc, DC, Sr. Director of Investor Relations (Age 46)

Has Sophiris Bio been receiving favorable news coverage?

News stories about SPHS stock have trended somewhat positive on Wednesday, according to Accern. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sophiris Bio earned a news sentiment score of 0.24 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 44.67 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Sophiris Bio's major shareholders?

Sophiris Bio's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.35%). View Institutional Ownership Trends for Sophiris Bio.

Which major investors are selling Sophiris Bio stock?

SPHS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Sophiris Bio.

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $3.79.

How big of a company is Sophiris Bio?

Sophiris Bio has a market capitalization of $112.92 million. The biopharmaceutical company earns $-8,620,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]

MarketBeat Community Rating for Sophiris Bio (SPHS)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.